BOOTCAMP IS BACK

Summer Boot Camp is here! Classes are scheduled to begin Monday June 12th – Friday June 16th at 7pm ET. You can attend live, or at your leisure. All meetings are recorded and sent to you for you to keep.

If you haven’t yet attended one of our camps, now’s the time to give it a shot.

Each year, the content is molded to thoughtful insight on market direction, shorter term/longer term market rotations and positioning, current analysis on various asset classes and instruments, as well as thought out predictions and actionable ideas for trading accounts and investment portfolios.

Here’s the scheduled content:

Monday: How the Pro’s are Positioned: Fund Flows, Cash and Rotations.
Tuesday: Should You Go Away Or Stay and Play This Summer?
Wednesday: Opportunities and Risks of a Single Digit VIX.
Thursday: Bonds, Gold or Bitcoins?
Friday: Pain Trades and Top Ideas Through 2017.

CLICK HERE TO REGISTER

Please contact me with any questions: [email protected]

See you there!

We’re far enough along in this rally that people are gravitating solely towards riskier instruments.

Take a look at these charts…

Growth stocks are in a full blown uptrend and value stocks are in a downtrend.

Is this the stage where you look at your portfolio and decouple from old man stocks?

Maybe you sell some $MO for some $MOMO? Some $DD for $DDD?

It’s fair to say that in this leg of our beloved bull market, not many took advantage of prices offered in late 2015 – early 2016. Even when the headlines of January 2016 were “sell everything” and “worst start for markets in history” people wanted very little to do with fire sale prices.

Lol.

Even while the market trended mostly uninterrupted in 2016, the attitude was “fuck it, it’s rigged anyway.” Supposing that’s true, it’s a compelling argument to not participate in a market that only goes higher because you have a good conscience.

Lol.

So now that the angle of this trend is steepening, it represents a shift. In the rear view, it’s safe to say that late 2015 and early 2016 was an accumulation phase. That phase leads into public participation phase. That phase takes awhile to take those that chose market abstinence and condition them towards impregnating every single stock that offered a downtick…sorta like I’ve been doing over here for years now.

With the stories of $AMZN, Bitcoins, $TSLA, $FANG’s…etc there are more reasons for folks to step out into the unknown and donate their money to market. This phase takes time, and it’s a very strong current that can lack rational movements, decisions and defy odds. It’s important to remember that while all this action is so very tempting, the exit is always smallest at the slightest sign of change.

Moving forward, I still like the idea of using market sentiment metrics to determine where things overheat. It’s quite likely that this might be hard to gauge, since there will be things we haven’t seen a whole lot in decades.

Enjoy the ease and simplicity, but try to think above the crowd level. Environments like late 2015-early 2016 don’t give me anxiety, because nobody wants to buy. However, these environments give me lots of anxiety. I hate it when more and more people want a piece of the action.

Good day.

Let’s play a game of Turd Roulette. I’ll kick off a focus group this week for those like myself, with nothing better to do.

Here are my top few findings so far from my trash bin search…

$IDRA

$CBAY

$ATEN

$VNET

$GRPN

I’m starting with a round of poo, before I go total shit list.

What’s your best idea here given the genre?

Mid-May is where I like to adjust my approach to sniff out the shittiest stocks I can find and use them to fund my summer activities.

Today, I am starting with $KNDI, which is right in line with my China theme, and is on the cusp of breaking out.

Over the next few months, when you see some tickers that instantly make you want to vomit, you’ll know why I’m pursuing this as a strategy.

Bon Appétit.

My long in $PBYI just paid off big time this morning. Closed half at $63 from $32, leaving the other half for early retirement.

May 22, 2017 10:08 AM ET (BZ Newswire) — Press Releases

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company,

announced that the U.S. Food and Drug Administration (FDA) posted briefing

documents on its website in preparation for the May 24 Oncologic Drugs

Advisory Committee (ODAC) meeting scheduled to review PB272 (neratinib)

for the extended adjuvant treatment of HER2-positive early stage

breast cancer.

ODAC is an independent panel of experts that evaluates data concerning

the efficacy and safety of marketed and investigational cancer

treatments and makes appropriate recommendations to the FDA. Its

comments are not binding, but are considered by the FDA in its

decision-making process.